Inhibition of molecular targets for the treatment of non-Hogkin lymphomas. Activation of oncogenes is a critical event in the development of non-Hodgkin lymphomas. Oncogenic proteins are key effectors in signaling pathways that regulate cell proliferation, cell cycle progression, and apoptosis. Their inhibition via specific small molecules and pharmacologic agents offers a novel approach in the targeted treatment of non-Hodgkin lymphomas. While several have already entered clinical trials with promising preliminary results, other agents are still awaiting preclinical validation. LMW indicates low molecular weight; CAK, CDK-activating kinase.